Detail
| LncRNA Name | BCAR4 |
| Synonyms | NA |
| Region | GRCh38_16:11819829-11828845 Sequence |
| Ensembl | ENSG00000262117 |
| RefSeq | NR_024049 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | microarray, qPCR, RNAi etc. |
| Sample | cell lines (ZR-75-1, MCF7, BCAR4 etc.) |
| Expression Pattern | differential expression |
| Function Description | As BCAR4 expression in cell lines did not change the sensitivity to different chemotherapeutic agents, the increased sensitivity to lapatinib is not due to a general mechanism of drug resistance. Also in our BCAR4-expressing cell models, the combination of lapatinib and antioestrogens was more potent in inhibiting cell growth than lapatinib alone; indicating that blocking the ERBB2 pathway with lapatinib re-sensitises BCAR4-expressing cells to antioestrogens. BCAR4 expression strongly sensitised ZR-75-1 and MCF7 breast cancer cells to the combination of lapatinib and antioestrogens. |
| Pubmed ID | 22892392 |
| Year | 2012 |
| Title | BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. |
| External Links |
| Links for BCAR4 | GenBank HGNC lncrnadb Noncode |
| Links for breast cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.